Europe approves GlaxoSmithKline's new triple lung drug

LONDON (Reuters) - Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair.